[ET Net News Agency, 12 October 2021] Venus Medtech (Hangzhou) Inc. (02500) said the
National Medical Products Administration (NMPA) has officially accepted the registration
application of TriGUARD3, the cerebral embolic protection (CEP) device, submitted by the
company.
TriGUARD3 is used in transcatheter aortic valve replacement procedures, which deviates
embolic fragments from the cerebral circulation, so as to minimize the risk of harm caused
to brain. TriGUARD3 is the only CEP device that has obtained the CE Marking designed to be
used in TAVR procedures to cover the whole ascending aorta. (RC)